Study results showed that combining Videssa® Breast with imaging improves breast cancer detection and significantly reduces the total number of biopsies and false positives (benign biopsies) in patients with abnormal imaging findings. Results below are from clinical trial Provista 002 Cohort 1, which examined women ages 25 to 75 with a BI-RADS 3 or 4 assessment.
Videssa Breast would have reduced the total number of biopsies by 63 percent.
Videssa Breast would have reduced the rate of false positives by 73 percent.
Provista has conducted two prospectively collected, randomized, blinded, multi-center clinical trials, which enrolled patients from 15 sites across the US to evaluate the ability of Videssa Breast to detect the presence or absence of breast cancer in patients with abnormal imaging findings.